On August 4, IDEXX Laboratories rose 5.29% in pre-market trading, trading at $571.0/share, with turnover of $1.369 million. The move was triggered by the company's release of its second fiscal quarter earnings report before market open, with the Street expecting adjusted earnings per share of $3.95.

In Q1, IDEXX reported revenue of $1.141 billion, beating the consensus estimate of $1.109 billion, though adjusted EPS of $3.30 fell slightly short of the $3.40 estimate. Despite the EPS miss, the company raised full-year guidance citing improved clinical visit volumes and higher diagnostic frequency at veterinary practices. On the product front, IDEXX has recently expanded its Fecal Dx antigen testing platform with tapeworm detection capabilities and launched a Cancer Dx Panel for early detection of canine lymphoma in the UK, broadening its diagnostic coverage. Analyst consensus maintains an overweight rating with a mean price target of $713.46, well above current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)